Upcoming Presentation by Rapafusyn Pharmaceuticals
Rapafusyn Pharmaceuticals is thrilled to announce an upcoming oral presentation at the notable Targeted Protein Degradation & Induced Proximity Summit. This event is set to take place soon and presents a remarkable opportunity to delve into cutting-edge developments in the field of drug discovery.
Key Highlights of the Presentation
Dr. Rick Ewing, the Vice President and Head of Chemistry at Rapafusyn, will present his insights on October 31. His presentation, titled "Non-Degrading Molecular Glues: A Platform for Finding Novel Chemical Matter for Inhibiting Intracellular & Transmembrane Proteins," aims to showcase Rapafusyn's innovative technologies, RapaGlues™ and RapaTags™, which are designed to enhance drug discovery processes significantly.
Innovative Drug Discovery Techniques
RapaGlues™ acts as a groundbreaking modality, enabling scientists to tackle challenging biological targets that previously resisted conventional approaches. In this presentation, Dr. Ewing will highlight how SAR (Structure-Activity Relationship) campaigns have yielded cell-permeable compounds that offer extended pharmacokinetic (PK) half-lives, representing a significant step forward in drug development.
Dr. Sean Hu's Insights on Progress
Dr. Sean Hu, CEO of Rapafusyn Pharmaceuticals, emphasizes the importance of their molecular glue platform, stating, "Our innovative non-degrading molecular glue platform has enabled significant advances in tackling difficult-to-drug targets. We are excited to share our progress at the Targeted Protein Degradation & Induced Proximity Summit." This showcases the commitment of Rapafusyn to advancing therapeutic options for various diseases.
About Rapafusyn Pharmaceuticals
At Rapafusyn, the mission is clear: to create non-degrading molecular glues aimed at previously hard-to-drug targets. Utilizing their cutting-edge FKBP12-binding macrocyclic peptide platform, they have developed vast DNA-encoded libraries (DELs) and arrayed libraries, providing novel starting points for drug development.
Targeting Intracellular Proteins
This innovative approach focuses on intracellular proteins and specific domains within transmembrane proteins such as SLCs, ion channels, and GPCRs. With a commendable modular design, Rapafusyn is able to rapidly optimize crucial drug properties, thereby accelerating the drug discovery timeline.
Contact Information
For more detailed insights into their upcoming research and initiatives, please visit their official website or reach out to Heather Lavin via email for inquiries and additional information.
Frequently Asked Questions
What is the focus of Rapafusyn's upcoming presentation?
Rapafusyn will present their advancements in non-degrading molecular glues and their application in drug discovery.
Who will be presenting at the Targeted Protein Degradation Summit?
Dr. Rick Ewing, the VP and Head of Chemistry at Rapafusyn, will deliver the presentation.
What solutions does Rapafusyn provide?
Rapafusyn Pharmaceuticals focuses on developing non-degrading molecular glues to target challenging biological elements in drug discovery.
How does Rapafusyn's platform stand out?
Their platform leverages natural modalities to address difficult-to-drug targets, enhancing the potential for novel therapeutic discoveries.
Where can I learn more about Rapafusyn Pharmaceuticals?
More information is available on their official website.
